Abstract
Breast cancer is the most common cancer, with the highest mortality rate and the most diagnosed cancer type in women worldwide. To identify the effect innate immune checkpoint for breast cancer immunotherapy, the innate immune prognostic biomarkers were selected through the ICI score model and the risk model in breast cancer patients. Moreover, the reliability and accuracy of the ICI score model and the risk model were further examined through the analysis of breast cancer prognosis and immune cell infiltration. The pan cancer analysis further confirmed and selected CXCL9 as the key innate immune checkpoint for breast cancer immunotherapy and identified three small molecular drugs for target CXCL9 through molecular docking analysis. In summary, CXCL9 significantly correlated with the prognostic of breast cancer and immune cell infiltration and could be innate immune checkpoint for breast cancer immunotherapy.
Highlights
Breast cancer is the most common cancer, with the highest mortality rate and the most diagnosed cancer type in women worldwide [1]
The high expression level of TIM-3 from tumor-associated dendritic cells significantly decreased innate immune response through its interact with HMGB1 and suppressed the recognition and recruitment of the molecular of nucleic acids [23]. These results suggested that the key role of innate immune response in the progress of tumors and may be the core element of the success of cancer immunotherapy
We identified 103 innate immune-related genes were significantly differentially expressed in breast cancer tissue samples compared with normal tissue samples (FDR < 0.05, |logFC| > 2; Figure S1A)
Summary
Breast cancer is the most common cancer, with the highest mortality rate and the most diagnosed cancer type in women worldwide [1]. The high expression level of TIM-3 from tumor-associated dendritic cells significantly decreased innate immune response through its interact with HMGB1 and suppressed the recognition and recruitment of the molecular of nucleic acids [23]. These results suggested that the key role of innate immune response in the progress of tumors and may be the core element of the success of cancer immunotherapy. The research study of innate immune response in cancer has made great progress, the effect innate immune checkpoints for cancer immunotherapy based on innate immune response systems still needs further exploration. Pan analysis for those 11 candidates innate immune response signatures and found that CXCL9 may be the key innate immune checkpoint for breast cancer therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
